Published on
Last updated on
1,002 Institutions in China Qualified for Clinical Trials
On June 1, 2021, the NMPA (National Medical Products Administration) published the list of institutions qualified for conducting clinical trials that have already completed their filing application to be listed in the NMPA database.
Since the NMPA issued the requirements and administration measures of qualified clinical trial institutions (No.145 - 2017) in November 2017, a total of 1,002 institutions have completed the filing application as of May 2021. The institutions listed in the NMPA database is currently open to public access under the website of the Center for Food and Drug Inspection in China.
By Colleen Xu. Contact Cisema if you would like to learn more.
Connect with Cisema
With more than 20 years of experience and a team of over 100 specialists, Cisema helps global companies achieve compliance across Asia Pacific with confidence and accelerate market entry.
Stay Informed with Monthly News and Analysis
Stay informed with the latest regulatory changes, expert insights, and market opportunities across APAC, delivered straight to your inbox.
Related News
China Expands MRI Registration Requirements Under New 2026 Review Guideline
Manufacturers seeking MRI registration in China must meet expanded technical, software, and validation requirements.
China CMDE Releases New Review Documents for Oncology NGS & HLA-B*58:01 Reagents
The new documents clarify expectations for Tier III variants, companion diagnostic clinical evaluation, tissue and plasma registration, and HLA-B*58:01 analytical validation.
Taiwan Extends Cosmetic GMP Requirements to Nearly All Manufacturing Sites
As of July 1, 2026, Taiwan has completed its cosmetic GMP rollout, extending mandatory ISO 22716-based manufacturing standards to nearly all cosmetic factories